抗血管生成分子抑制脑膜瘤诱导的血管生成：角膜血管生成研究。
Antiangiogenic Molecules Suppressed Meningioma-Induced Neovascularization: A Corneal Angiogenesis Study.
机构信息
University of Health Sciences, Dr. Lutfi Kırdar Kartal Training and Research Hospital, Department of Neurosurgery, Istanbul, Turkey.
出版信息
Turk Neurosurg. 2022;32(5):786-792. doi: 10.5137/1019-5149.JTN.34777-21.4.
AIM
To investigate the angiogenic effects of bevacizumab and imatinib on different meningioma tissue grades.
MATERIAL AND METHODS
In this study, in silico analysis of angiogenesis-related gene expression was carried out using previously reported datasets. Messenger ribonucleic acid expressions of VEGFA, VEGFB, PDGFRA, and PDGFRB genes were obtained from two different meningioma transcriptome datasets. The effect of antiangiogenic drugs, bevacizumab and imatinib, on meningiomainduced vascularization was assessed by using rat corneal angiogenesis assay (CAA).
RESULTS
Bevacizumab and imatinib both significantly reduced meningioma-induced neovascularization in the CAA model.
CONCLUSION
The angiogenic characteristics of meningiomas may be suppressed by using antiangiogenic drugs to prevent neovascularization, thus improving prognosis.
目的
研究贝伐珠单抗和伊马替尼对不同脑膜瘤组织级别的血管生成作用。
材料与方法
本研究采用已报道的数据集进行血管生成相关基因表达的计算机分析。从两个不同脑膜瘤转录组数据集获得 VEGFA、VEGFB、PDGFRA 和 PDGFRB 基因的信使核糖核酸表达。采用大鼠角膜血管生成试验（CAA）评估抗血管生成药物贝伐珠单抗和伊马替尼对脑膜瘤诱导的血管生成的影响。
结果
贝伐珠单抗和伊马替尼均显著降低 CAA 模型中的脑膜瘤诱导的新生血管形成。
结论
使用抗血管生成药物抑制脑膜瘤的血管生成特性可能有助于防止新生血管形成，从而改善预后。
Zotero 插件